T. Rowe Price Investment Management Inc. Has $42.90 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

T. Rowe Price Investment Management Inc. decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,697,498 shares of the biopharmaceutical company's stock after selling 37,024 shares during the period. T. Rowe Price Investment Management Inc. owned about 2.56% of Celldex Therapeutics worth $42,896,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $81,000. KBC Group NV raised its holdings in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 1,647 shares during the last quarter. AlphaQuest LLC lifted its position in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares in the last quarter. Finally, Aristides Capital LLC bought a new stake in Celldex Therapeutics during the 4th quarter worth about $202,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research report on Monday. They set a "buy" rating and a $64.00 target price on the stock. Morgan Stanley started coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, The Goldman Sachs Group reduced their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock traded down $0.12 during midday trading on Thursday, hitting $20.71. 621,747 shares of the company traded hands, compared to its average volume of 883,780. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -8.06 and a beta of 1.59. The firm's fifty day moving average price is $19.11 and its 200-day moving average price is $23.34.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. Equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.